SYM 2229Alternative Names: SYM-2229
Latest Information Update: 06 Nov 2006
At a glance
- Originator Annovis
- Mechanism of Action AMPA receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 06 Nov 2006 Discontinued - Preclinical for Epilepsy in USA (unspecified route)
- 13 Jan 2003 No development reported - Preclinical for Epilepsy in USA (unspecified route)
- 28 Nov 2000 Preclinical development for Epilepsy in USA (Unknown route)